期刊名称：CANCER CHEMOTHERAPY AND PHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims and scope
Addressing a wide range of pharmacologic and oncologic concerns on both experimental and clinical levels, Cancer Chemotherapy and Pharmacology is an eminent journal in the field. The primary focus in this rapid publication medium is on new anticancer agents, their experimental screening, preclinical toxicology and pharmacology, single and combined drug administration modalities, and clinical phase I, II and III trials. It is essential reading for pharmacologists and oncologists giving results recorded in the following areas: clinical toxicology, pharmacokinetics, pharmacodynamics, drug interactions, and indications for chemotherapy in cancer treatment strategy.
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed or comply with standards equivalent to the UKCCCR guidelines for the welfare of animals in experimental neoplasia (Br J Cancer 58: 109-113, 1988).
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfil the above-mentioned requirements.
Instructions to Authors
Manuscript submission
Manuscript Submission
Permissions
Online Submission
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities ¨C tacitly or explicitly ¨C at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please follow the hyperlink ¡°Submit online¡± on the right and upload all of your manuscript files following the instructions given on the screen.
Instructions to Authors
0344-5704.pdf
Editorial Board
Editorial Board
EDITORS-IN-CHIEF
Papers from all geographical areas
except North America and Japan to:
D. R. Newell
The University of Newcastle upon Tyne
Department of Clinical Oncology
Cancer Research Unit, Medical School
Framlington Place
Newcastle upon Tyne, NE2 4HH
United Kingdom
Tel.: +44-191-222-8057
Fax: +44-191-222-7556
E-mail: herbie.newell@ncl.ac.uk
Managing Editor: Sandra Cartwright
Papers from North America and Japan to:
M. J. Egorin
Professor of Medicine and Pharmacology
University of Pittsburgh Cancer Institute
Room G27E, Hillman Research Pavilion
5117 Centre Avenue
Pittsburgh, PA 15213-1863
USA
Tel.: +1-412-623-3252
Fax: +1-412-623-1212
E-mail: egorinmj@msx.upmc.edu
Managing Editors: Helen Spiker, Florence Wade
EDITORIAL BOARD
G. Abou-Alfa, New York, NY, USA
A. A. Adjei, Rochester, MN, USA
F. M. Balis, Bethesda, MD, USA
J. Beijnen, Amsterdam, The Netherlands
J. Beumer, Pittsburgh, PA, USA
A. Boddy, Newcastle upon Tyne, UK
J. Boos, M¨¹nster, Ireland
R. Brown, London, UK
J. Cassidy, Glasgow, Scotland
E. Chatelut, Toulouse, France
J. Collins, Rockville, USA
B. Conley, East Lansing, MI, USA
M. Fakih, Buffalo, NY, USA
Y. Fujiwara, Tokyo, Japan
V. Georgoulias, Heraklion, Greece
A. Gescher, Leicester, UK
G. Giaccone, Amsterdam, The Netherlands
J. L. Grem, Bethesda, MD, USA
P.J. Houghton, Memphis, TN, USA
D. Jodrell, Cambridge, Scotland
I. Judson, Sutton, UK
L. Lewis, Lebanon, NH, USA
R. Lock, Randwick, NSW, Australia
M. J. McKeage, Auckland, New Zealand
P. J. O'Dwyer, Philadelphia, PA, USA
I. N. Olver, Sydney, Australia
G.J. Peters, Amsterdam, The Netherlands
N. J. Petrelli, Buffalo, NY, USA
S. Pignata, Naples, Italy
R. Plummer, Newcastle upon Tyne, UK
W. Plunkett, Houston, TX, USA
S. S. Ramalingam, Atlanta, GA, USA
E. Raymond, Clichy, France
F. Raynaud, Sutton, UK
J. Robert, Bordeaux, France
M. L. Rothenberg, Nashville, TN, USA
Y. Sasaki, Saitama, Japan
J. Schellens, Amsterdam, The Netherlands
J. L. Speyer, New York, NY, USA
C.F. Stewart, Memphis, TN, USA
E. Strocchi, Bologna, Italy
T. W. Synold, Duarte, CA, USA
C. H. M. Takimoto, San Antonio, TX, USA
M. Villalona, Columbus, OH, USA
L. Webster, Mount Waverley, Australia
|
